Syntax Bio is a biotechnology company that develops a cell programming platform to control stem cell differentiation for research.
SyntaxBio has raised $14.4M in total funding. The most recent round was Series A. The last funding was announced in June 2026.
SyntaxBio's investors include Sigma Group, Draper Associates, DCVC Bio, Illumina Ventures, Mayo Clinic.
SyntaxBio is headquartered in Chicago, United States.
Syntax Bio is a biotechnology company that develops a cell programming platform to control stem cell differentiation for research.
SyntaxBio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SyntaxBio — Funding & Investors." VCBacked, June 21, 2026, https://www.vcbacked.co/company/syntaxbio. Accessed July 19, 2026.
VCBacked. (2026). SyntaxBio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/syntaxbio
{{cite web |title=SyntaxBio — Funding & Investors |url=https://www.vcbacked.co/company/syntaxbio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated